Clinical Trials Logo
  1. Home
  2. HIV Infections
  3. NCT00033163
  4. Details
NCT00033163 Clinical Trial

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

HIV Infections Clinical Trial

Official title:
A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00033163
Other study ID # A5127
Secondary ID 10678ACTG A5127A
Status Completed
Phase Phase 2
First received
Last updated
Est. completion date May 2005

Study information
Verified date October 2021
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Control of hepatitis B virus (HBV) infection can be difficult in HIV infected people who have taken the antiviral lamivudine (3TC). These people may have HBV that has become resistant to 3TC. Adefovir dipivoxil (ADV) has shown promising anti-HBV activity in clinical trials; tenofovir disoproxil fumarate (TDF) is used to treat HIV and may also be effective against HBV. The purpose of this study is to find out if adding ADV or TDF to a highly active antiretroviral therapy (HAART) regimen that includes 3TC has an effect on HBV infection in patients coinfected with HIV and HBV. The tolerability and safety of these drugs will be examined.

Description:

HBV presents a worldwide health crisis and is difficult to treat when a patient's HBV strain is no longer responsive to 3TC. Given the significant incidence of 3TC-resistant HBV in patients receiving this drug as part of an antiretroviral regimen, other agents with anti-HBV activity are needed. ADV has shown promising anti-HBV activity in preclinical assessments and in Phase I, II, and III clinical trials. TDF, developed for the treatment of HIV infection, has in vitro activity against HBV. This study will compare TDF/3TC combination therapy with ADV/3TC combination therapy to determine which treatment regimen is more effective in patients coinfected with HBV and HIV. This study will include two populations of patients. Patients in Population A are on stable HAART that includes TDF and will either be in Group I (compensated liver disease) or Group II (decompensated liver disease). All patients in Population A will be randomly assigned to one of two arms: Arm 1 patients will receive 10 mg ADV daily and TDF placebo; Arm 2 patients will receive ADV placebo and 300 mg TDF. Patients in Population B are on stable HAART and have never taken TDF as part of their HAART. Population B patients will receive 300 mg TDF daily during the course of the study. Study visits will occur every 4 weeks for the 96-week study period. Targeted clinical and medication assessments and blood work assessing clotting time, liver function, and blood chemistry will be conducted at each study visit. HIV and HBV DNA viral load will be tested every 12 weeks. CD4 cell counts will be tested at Weeks 24, 48, 72, and 96.

Recruitment information / eligibility
Status Completed
Enrollment 90
Est. completion date May 2005
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for All Participants: - HIV infected - HBV infected - Serum HBV DNA of 100,000 copies/ml or greater - Positive for serum hepatitis B surface antigen (HBsAg) within 12 weeks prior to study entry - Agree to use acceptable methods of contraception - Serum alpha-fetoprotein (AFP) of 50 ng/ml or less within 30 days of study entry. If AFP is greater than 50 ng/ml, the patient must have an imaging study of the liver showing no tumor within 30 days prior to study entry Inclusion Criteria for Population A: - Uninterrupted stable HAART regimen at study entry for at least 12 continuous weeks prior to study entry - HIV viral load of 10,000 copies/ml or less within 12 weeks of study entry Inclusion Criteria for Population A, Group I: - Compensated liver disease - Child-Pugh-Turcotte (CPT) score of less than 7 Exclusion Criteria for Population A, Group I: - Excess fluid in the space between the membranes lining the abdomen and abdominal organs (ascites) - Gastrointestinal (variceal) bleeding - Brain and nervous system damage as a result of liver disease - Abnormal blood clotting time Inclusion Criteria for Population A, Group II: - Decompensated liver disease - CPT score of 7-12 Inclusion Criteria for Population B: - Prior HAART regimen - Never taken TDF as part of HAART regimen - Serum HBV DNA of 100,000 copies/ml or greater within 12 weeks of study entry - HIV viral load of greater than 10,000 copies/ml within 12 weeks of study entry - CPT score less than 13 Exclusion Criteria - Serious kidney problems within the last 12 months - Allergic or sensitive to ADV or TDF - Active hepatitis C virus (HCV) disease or unknown HCV status within 24 weeks of study entry - Any medical or mental illness that, in the opinion of the investigator, would interfere with the protocol - Past or current alcohol or drug abuse that would affect the protocol - Malignancy that, in the opinion of the investigator, would make the patient unsuitable for the study - Certain anti-HBV drugs within 90 days of study entry or expected use of these agents during the course of the study - Drugs that may damage the kidneys within 8 weeks prior to study screening or expected use of these agents during the course of the study - Systemic corticosteroids within 90 days of study entry - Current use of drugs containing pivalic acid - Certain investigational anti-HIV agents - Pregnant or breastfeeding

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Adefovir dipivoxil

• Tenofovir disoproxil fumarate

Locations
Country Name City State
United States University of Colorado Hospital CRS Aurora Colorado
United States Johns Hopkins Adult AIDS CRS Baltimore Maryland
United States Cook County Hosp. CORE Ctr. Chicago Illinois
United States Northwestern University CRS Chicago Illinois
United States Univ. of Cincinnati CRS Cincinnati Ohio
United States MetroHealth CRS Cleveland Ohio
United States Vanderbilt Therapeutics CRS Nashville Tennessee
United States Beth Israel Med. Ctr., ACTU New York New York
United States Cornell CRS New York New York
United States NY Univ. HIV/AIDS CRS New York New York
United States Weill Med. College of Cornell Univ., The Cornell CTU New York New York
United States UC Davis Medical Center Sacramento California
United States Univ. of California Davis Med. Ctr., ACTU Sacramento California
United States Ucsf Aids Crs San Francisco California
United States University of Washington AIDS CRS Seattle Washington

Sponsors (1)
Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

References & Publications (6)

Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001 Sep 1;358(9283):718-23. — View Citation

Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999 Nov;30(5):1302-6. — View Citation

Dieterich DT. HIV and hepatitis B virus: options for managing coinfection. Top HIV Med. 2003 Jan-Feb;11(1):16-9. Review. — View Citation

Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B; ACTG Protocol A5127 Team. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B v — View Citation

Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S59-65. Review. — View Citation

Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003 May;23(2):125-36. Review. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2

External Links